Brief: DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
10/11/2025 12:14
Nov 10 (Reuters) - Daiichi Sankyo Co Ltd 4568.T: DS3610 ENTERS CLINICAL DEVELOPMENT IN PATIENTS WITH ADVANCED SOLID TUMORS AS FIRST STING AGONIST ADC IN INDUSTRY-LEADING ADC PORTFOLIO OF DAIICHI SANKYO Source text: ID:nBw99nSbka Further company coverage: 4568.T ((reuters.briefs@thomsonreuters.com;))